UseCases_ArguminSci_Discourse  

PubMed:18797249 JSONTXT 4 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-158 DRI_Challenge denotes Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats.
T2 159-397 DRI_Background denotes Subchronic treatment with memantine using osmotic pumps in male rats was used to verify whether plasma levels significantly blocking L-N-methyl-D-aspartate (NMDA) receptors (and shown previously to be neuroprotective) may impair learning.
T3 398-498 DRI_Unspecified denotes Treatment with 6.27, 12.5 and 18.8 mg/rat/day provided plasma levels of 1.03+/-0.08, 5.07+/-0.68 and
T4 499-522 Token_Label.OUTSIDE denotes 11.68+/-0.90 micromol/l
T5 522-523 DRI_Unspecified denotes .
T6 524-633 DRI_Background denotes Only the lowest plasma level is therapeutically relevant and has previously been shown to be neuroprotective.
T7 634-722 DRI_Outcome denotes Significant deficits in a passive avoidance task were only observed at the highest dose.
T8 723-883 DRI_Approach denotes Working memory, tested as spontaneous alternation in the cross maze, was impaired by the middle and highest doses, and these doses also induced hyperlocomotion.
T9 884-997 DRI_Outcome denotes Microdialysis experiments with in-vivo recovery (27.4%) showed that infusion of memantine at 6.27 mg/rat/day (ca.
T10 998-1039 DRI_Background denotes 23 mg/kg/day) produced a concentration of
T11 1040-1056 Token_Label.OUTSIDE denotes 990+/-105 nmol/l
T12 1057-1080 DRI_Background denotes in extracellular fluid.
T13 1081-1286 DRI_Background denotes In-vivo NMDA receptor occupancy experiments demonstrated significant, dose-dependent receptor occupancy of 32.7 and 65.7% by memantine at the doses producing 1 and 5 micromol/l plasma levels, respectively.
T14 1287-1460 DRI_Background denotes Moreover, acute administration (2.5 mg/kg intraperitoneally) of memantine to mature female rats produced approximately two-fold higher plasma levels than in young male rats.
T15 1461-1738 DRI_Challenge denotes In conclusion, a dose of memantine which produces a plasma level (1 micromol/l) within the therapeutic range, reported previously to be neuroprotective, leads to intracellular brain levels similar to the affinity of memantine for NMDA receptors (receptor binding, patch clamp).
T16 1739-1851 DRI_Background denotes This has been also extended by the experiments showing that at this plasma concentration, memantine occupies ca.
T17 1852-1921 DRI_Outcome denotes 30% NMDA receptors in the brain and produces no cognitive impairment.